Cargando…
Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records
BACKGROUND: New treatments for transthyretin amyloidosis improve survival, but diagnosis remains challenging. Pathogenic or likely pathogenic (P/LP) variants in the transthyretin (TTR) gene are one cause of transthyretin amyloidosis, and genomic screening has been proposed to identify at-risk indivi...
Autores principales: | Carry, Brendan J., Young, Katelyn, Fielden, Samuel, Kelly, Melissa A., Sturm, Amy C., Avila, J. David, Martin, Christa L., Kirchner, H. Lester, Fornwalt, Brandon K., Haggerty, Christopher M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543083/ https://www.ncbi.nlm.nih.gov/pubmed/34746851 http://dx.doi.org/10.1016/j.jaccao.2021.07.002 |
Ejemplares similares
-
Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020) -
Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023) -
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023) -
Speckle Tracking and Transthyretin Amyloid
Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017) -
Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)